Navigation Links
Pinnacle Biologics Announces Contract With Chiltern
Date:6/23/2008

ROCKVILLE, Md., June 24 /PRNewswire/ -- Pinnacle Biologics, a private, full-service pharmaceutical and biotech solutions company, today announced it has entered into an agreement with Chiltern International, Inc. for the activities of pharmacovigilence/safety reporting and medical information services for Western Europe.

James R. Miller, President & CEO of Pinnacle Biologics stated, "The completion of the Chiltern agreement represents a significant step in the process of offering a full range of services and solutions to the pharmaceutical/biotechnology companies that we currently represent or will partner with in the future. We are proud to be associated with Chiltern."

"Chiltern is extremely excited about expanding our service portfolio to meet the Pinnacle Biologics unique Pharmocovigilence, Safety and Medical Information requirements and help accelerate the commercialization of pharmaceutical products that are promoted and distributed by Pinnacle," noted Glenn Kerkhof, Chief Executive Officer of Chiltern

About Pinnacle Biologics

Founded in 2007 by health care executives Guillermo Herrera, James Miller, and Viren Grover, Pinnacle Biologics is a premier international company that excels in assisting pharmaceutical and biotech companies that require a total solution in either launching products or maximizing/monetizing the value of products late in their life cycle. Pinnacle forms exclusive relationships with research-based pharmaceutical multi-national corporations and biotechnology companies to take products to the next level.

Pinnacle provides a full range of services including regulatory, sales, marketing, distribution (including billing and collections), pharmacovigilence, product safety, market research and administrative services.

Pinnacle holds executive offices in Bannockburn, Illinois, satellite offices in Rockville, Maryland, and Almere, The Netherlands. Further information is available at http://www.pinnaclebiologics.com

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research Organization with extensive experience conducting and staffing international Phase I to Phase IV clinical trials across a broad range of therapeutic areas for a wide variety of clients. Chiltern employs more than 1,200 people with 23 offices across the United States, Europe, Latin America and in India. Chiltern provides services including Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Further information is available at http://www.chiltern.com

COMPANY CONTACT:

James R. Miller, Pinnacle

President & CEO

1(240)372-4599


'/>"/>
SOURCE Pinnacle Biologics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pinnacle Biologics Announces Logistics Services Agreement With the Movianto Group
2. Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis
3. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
4. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
5. Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit
6. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
7. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
8. MedImmune Submits Biologics License Application to FDA for Motavizumab
9. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
10. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
11. Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... YM (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. ... microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory and ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... BEACH, Calif. , June 23, 2016  Blueprint ... new biological discoveries to the medical community, has closed ... co-founder Matthew Nunez . "We have ... us with the capital we need to meet our ... will essentially provide us the runway to complete validation ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):